What is the latest market price of neratinib/neratinib in 2025?

Neratinib/Neratinib (Neratinib) is an irreversible pan-ErbB receptor tyrosine kinase inhibitor that mainly targets HER2 (human epidermal growth factor receptor 2) and its related receptors, such as EGFR and HER4. The drug was originally developed by Puma Biotechnology and is mainly used to treat patients with early-stage HER2-positive breast cancer, especially those who are at high risk of recurrence after completing adjuvant treatment with trastuzumab (Herceptin). Neratinib blocks the growth and proliferation of tumor cells by continuously inhibiting the HER2 signaling pathway. What is different from traditional HER2-targeted drugs is its irreversible binding properties, which makes it possible to maintain efficacy in some drug-resistant cases.

Neratinib has been approved in the United States and Europe for the treatment of early-stage HER2-positive breast cancer and is recommended as a continuation treatment after trastuzumab treatment. In the Chinese market, neratinib has been approved for marketing in recent years and has been included in the national medical insurance catalog as a Class B drug, which means that patients can obtain a certain percentage of cost reimbursement through medical insurance. According to public data, its product specifications in China are usually 40 mg × 180 tablets/box, and the price is about RMB 15,000. After medical insurance reimbursement, the patient's out-of-pocket cost is greatly reduced, but the applicable population still needs to be determined strictly in accordance with the indications and treatment cycles specified in the drug instructions.

In overseas markets, the price of the original drug Neratinib is significantly higher than that in the domestic market. The price in the U.S. market may be as high as more than 10,000 US dollars per box, which also makes the drug extremely expensive to use in countries and regions that do not receive medical insurance support. Fortunately, as the patent protection period gradually comes to an end, some emerging market countries such as Bangladesh and India have launched generic versions of neratinib. For example, the generic version of 40 mg × 180 tablets produced by manufacturers such as Bangladesh Yaopin International is priced at about 2,000 to 3,000 yuan, becoming an important alternative to the high price of the original drug.

Reference materials:https://en.wikipedia.org/wiki/Neratinib